These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36094202)

  • 1. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
    Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Clin Drug Investig; 2023 Oct; 43(10):785-797. PubMed ID: 37798608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
    Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA
    Tsuge Y; Ariwa Y; Shibata K
    Nihon Yakurigaku Zasshi; 2024; 159(4):264-281. PubMed ID: 38945910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
    Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
    Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    Medicine (Baltimore); 2023 Feb; 102(8):e33024. PubMed ID: 36827007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensitrelvir Fumaric Acid: First Approval.
    Syed YY
    Drugs; 2024 Jun; 84(6):721-728. PubMed ID: 38795314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
    Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Sakaguchi H; Sonoyama T; Ichihashi G; Sanaki T; Baba K; Tsuge Y; Uehara T
    Clin Infect Dis; 2023 Apr; 76(8):1403-1411. PubMed ID: 36477182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.
    Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Fukushi A; Imamura T; Sakaguchi H; Sonoyama T; Sanaki T; Ichihashi G; Tsuge Y; Uehara T; Mukae H
    Antiviral Res; 2024 Sep; 229():105958. PubMed ID: 38972603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
    Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
    Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
    Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review.
    Yamato M; Kinoshita M; Miyazawa S; Seki M; Mizuno T; Sonoyama T
    J Infect Chemother; 2024 Sep; 30(9):946-950. PubMed ID: 38367932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
    Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
    J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
    Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Bac NH; Cha BK; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    JAMA Netw Open; 2024 Feb; 7(2):e2354991. PubMed ID: 38335000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.
    Ohmagari N; Yotsuyanagi H; Doi Y; Yamato M; Imamura T; Sakaguchi H; Yamanaka H; Imaoka R; Fukushi A; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13338. PubMed ID: 38890511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: Case series.
    Tomita T; Miyazawa S; Sonoyama T
    Medicine (Baltimore); 2024 Jul; 103(30):e39080. PubMed ID: 39058834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.